Trial Transformation: A Discussion with Sites on Improving Patient Outcomes with Digital Technology

Sponsored by: IQVIA

MaryAnne Rizk, PhD, Senior Vice President, R&D Digital Strategy, IQVIA
Larissa Harrison, Regional Director, Avacare

Thursday - June 11, 2020 / 1:00pm EDT
Free Event

Register Now

In the current environment, amid the wake of COVID-19, there is an anticipated but significant increase in demand for virtual or hybrid trials with remote/centralized site monitoring and patient enablement services. With sites increasingly proving to be inaccessible across the globe for patients, site staff and/or site monitors, and regulators halting inspections, the biopharma industry is facing many new challenges to ensure patient safety, compliance, and data quality and integrity. Concurrently, life science stakeholders must come together join the global effort of driving healthcare forward

Trimming the 10 years and $2.6B to develop a new drug and eliminate the siloes of data is key to minimizing risk or maximizing value during the drug or vaccine development process. Often, a ‘domino effect’ that starts with siloed functions, business processes, data and technology, continues with startup delays, site failures, slow enrollment, and unhappy sites – and ends with delayed regulatory submission. Today, as we mobilize together: this is no longer sustainable. Sites, sponsors, and our industry must find a path forward for patients: and digital collaboration is paramount

While sponsors have often developed their own ways to store and analyze data, most of the outputs are more descriptive analyses of the data, rather than strategic, outcomes-based actions. As organizations start to build more predictive and prescriptive algorithms that help guide the workforce with patient referrals for clinical trials, matching of clinical trials to patient need and trial applicability, and measuring the results of subsequent action, a different type of platform architecture is needed for everyone to do their part to ensure that patients are . New, virtual or decentralized engagement models will emerge as we mitigate the impact of COVID-19, together.

This webinar will feature a panel of life science experts discussing how to increase clinical productivity, focus on protocol risks, conduct remote monitoring, improve sponsor transparency and orchestrate process hand-offs across functions. This talk will highlight how digitally connecting previously siloed applications and departments enables a seamless trial management experience – combined with actionable insights that can speed time to market, and offer patients a safe, de-centralized experience in the current environment.

Learning points:

  • Increase clinical productivity and improve patient outcomes through digital engagement from an end-to-end and supply chain perspective
  • Leverage data-driven insights to gain transparency, interoperability to focus on the “next-best actions” for staff
  • Breakdown of internal data silos for a seamless, virtual trial management experience that enables patient referrals by physicians for clinical research and a more seamless experience for all stakeholders
  • Real-time industry brainstorm: Our responsibility as a life science industry to help sites with virtual recruitment efforts

About the Sponsors

For more information please visit

Posted in: Clinical Trials, R&D

Comments are closed.